Covid-Fisetin: Pilot in Covid-19 of Fisetin to Alleviate Dysfunction and Inflammation

Covid-Fisetin: Pilot in Covid-19 of Fisetin to Alleviate Dysfunction and Inflammation

Publication date: Jul 20, 2020

The purpose of this study is to test whether Fisetin, a senolytic drug, can assist in preventing an increase in the disease’s progression and alleviate complications of coronavirus due to an excessive inflammatory reaction.

Concepts Keywords
Alanine Aminotransferase Infection
Allergy SARS
ALT Increase disease
Antifungals Absolutely infectious perspective
Ascites CoV infection
Aspartate Transaminase Medical specialties
AST Intensive care medicine
Attending Physician Catechols
Bilirubin Fisetin
Blood Flavonols
Cardiovascular Extracorporeal membrane oxygenation
Coronavirus Coronavirus disease
Cyclosporine Senolytic
CYP2C8 Chemistry
CYP2C9
CYP2D6
CYP3A4
ECMO
EGFR
Endocrine
Fungal Infection
Glucose
Hemoglobin
Hepatic
Hepatitis
Hospital
Hypersensitivity
ICH
Immunodeficiency
Infection
Inflammation
Inflammatory Reaction
Informed Consent
Lymphocyte
Mayo Clinic
Melanoma
Menopausal
NIH
Oxygen
Oxygenation
PCR
Pericardial Effusions
Platelet
Pleural
Proton Pump Inhibitors
Randomization
Renal
SARS
Sirolimus
SpO2
Substrates
Tacrolimus
Therapeutic Range
Tolerability
Virus
WHO

Semantics

Type Source Name
drug DRUGBANK Fisetin
disease MESH Inflammation
disease MESH complications
disease MESH infection
disease MESH emergency
disease MESH Men
drug DRUGBANK L-Alanine
disease MESH renal
drug DRUGBANK Dextrose unspecified form
disease IDO immunodeficiency
disease MESH virus infection
disease MESH hepatitis B
pathway KEGG Hepatitis B
disease MESH Invasive fungal infection
disease MESH pericardial effusions
disease MESH ascites
disease MESH cancer
disease MESH melanoma
pathway KEGG Melanoma
disease MESH skin cancers
disease MESH hypersensitivity
drug DRUGBANK Ciclosporin
drug DRUGBANK Tacrolimus
drug DRUGBANK Sirolimus
disease MESH infectious disease

Original Article